Owens J∥Nat Rev DrugDiscov.-2007,6(3).-187成药能力,即小分子药物调节靶点的可能性,是确定药物开发是否可以从“苗头”发展到“先导化合物”的关键。约10%的人类基因组可成为药靶,其中仅半数与疾病相关,在药物开发的早期阶段预测一个新靶点的成药性非常重要。靶点的成药能 Owens J∥Nat Rev DrugDiscov.-2007,6 (3) .- 187 The ability of small-molecule drugs to modulate targets is the key to determining whether drug development can progress from “signs” to “lead compounds.” About 10% of the human genome can become a drug target, of which only half are disease-related. Predicting the drug-drug potential of a new target in the early stages of drug development is very important. Target drug into medicine